Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752297 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows
A Phase 3 study, sponsored by Mentor Worldwide.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00752297 is a Phase 3 study that has completed, run by Mentor Worldwide. The registered enrollment target is 402 participants.
The verdict
NCT00752297, a Phase 3 study, has completed, sponsored by Mentor Worldwide.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
The overall purpose of this study is to evaluate the safety and effectiveness of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
Interventions
- DRUG Preservative-free Saline
- DRUG Mentor Purified Toxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752297
The ClinicalTrials.gov registry entry for NCT00752297 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mentor Worldwide, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Preservative-free Saline is the first listed.
NCT00752297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752297 about?
NCT00752297 is a clinical study titled "Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows". The overall purpose of this study is to evaluate the safety and effectiveness of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
What is the current status of trial NCT00752297?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2007-06. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00752297?
The interventions under investigation include: Preservative-free Saline (DRUG), Mentor Purified Toxin (DRUG).
Who is sponsoring clinical trial NCT00752297?
This trial is sponsored by Mentor Worldwide, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.